Eiger Biopharmaceuticals Secures $1,057,568 Series A Round

  • Feed Type
  • Date
    8/30/2012
  • Company Name
    Eiger Biopharmaceuticals
  • Mailing Address
    PO Box 430 San Carlos, CA 94070
  • Company Description
    Eiger BioPharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger’s pipeline includes repurposed clinical agents as well as preclinical new chemical entities (NCEs) from its discovery research shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.
  • Website
    http://www.eigerbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $1,057,568
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor
    Undisclosed